Microbot Medical Inc

Microbot Medical Inc has a market capitalization of $124.24 million and a price-to-book ratio of 20.52, indicating a premium valuation relative to its book value. The company holds $2.47 million in cash and equivalents, with no long-term debt, resulting in a debt-to-equity ratio of 0.0 and a current ratio of 5.32, suggesting strong short-term liquidity. However, the company reported negative operating cash flow of -$4.38 million and free cash flow of -$2.46 million, indicating ongoing cash burn. The company's financial performance shows significant underperformance relative to typical industry metrics. It reported a net loss of $2.47 million and operating loss of $2.51 million, with return on equity (ROE) of -40.71% and return on assets (ROA) of -33.16%. These metrics suggest the company is not generating returns for shareholders or efficiently utilizing its assets. The enterprise value to EBITDA ratio is negative at -48.50, reflecting the company's unprofitable operations. Microbot Medical Inc operates as a single-segment entity, with no disclosed geographic revenue breakdown. The company's total assets of $7.43 million and total equity of $6.06 million suggest a relatively small asset base, with no material revenue concentration risks identified in the available data. The company's growth trajectory is uncertain, with no specific revenue growth rates provided in the available data. Analysts have assigned a mean price target of $7.50 and a median price target of $5.50, with three "buy" ratings and no "strong buy" ratings. The absence of positive earnings and the company's ongoing cash burn raise concerns about its ability to sustain operations without additional capital. Risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative cash flows and lack of profitability represent operational risks. The risk of dilution remains low, with no recent issuance or shelf registration activity reported in the available data. Recent events include the publication of the latest financial data, which shows continued losses and cash burn. No material regulatory or litigation events were disclosed in the available data. The company's reliance on external financing to fund operations remains a key risk factor.